Business
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss
NEW HAVEN, Conn., April 27, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 clinical trial (Study ‘302’) evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in over 500 males with mild-to-moderate pattern hair loss. Veradermics b
About this update from Veradermics, Incorporated
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3613,"height":584,"url":"https://media.zenfs.com/en/business-wire.com/fbf1d67692d0afa91a774360f669c811"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/m1WRoQGap3P8RBdsJ6o8IA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE1NQ--/https://media.zenfs.com/en/business-wire.com/fbf1d67692d0afa91a774360f669c811","width":960,"height":155},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/pjV5Gd5AqGC9idaYtxTuDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zODg-/https://media.zenfs.com/en/business-wire.com/fbf1d67692d0afa91a774360f669c811","width":1200,"height":194}},"lazy":false},{"type":"text","content":"VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01","length":264,"tagName":"p","attribs":{}},{"type":"text","content":"Rapid and robust hair growth was achieved with VDPHL01 treatment as demonstrated by a mean increase in non-vellus target area hair count (TAHC) of 30.3 hairs/cm² (once daily dosing; p<0.0001) and 33.0 hairs/cm² (twice daily dosing; p<0.0001) versus 7.3 hairs/cm² for placebo at Month 6","length":291,"tagName":"p","attribs":{}},{"type":"text","content":"Approximately 79.3% (QD) and 86.0% (BID) of patients reported any improvement in patient-reported outcomes (PRO) versus 35.6% of placebo patients; 48.4% (QD; p<0.0001) and 62.9% (BID; p<0.0001) of patients reported ‘improved’ or ‘much improved’ outcomes at Month 6 versus 13.4% of placebo patients","length":303,"tagName":"p","attribs":{}},{"type":"text","content":"Statistically significant improvement in hair growth was observed at Month 2, the earliest time point evaluated","length":111,"tagName":"p","attribs":{}},{"type":"text","content":"VDPHL01 demonstrated a favorable safety and tolerability profile with overall adverse event rates similar to placebo","length":116,"tagName":"p","attribs":{}},{"type":"text","content":"VDPHL01 has the potential to become the first FDA-approved non-hormonal oral treatment for the approximately 80 million men and women with pattern hair loss in the U.S.","length":168,"tagName":"p","attribs":{}},{"typ...